Alnylam Pharmaceuticals is a biopharmaceutical company engaged in developing novel therapeutics based on RNA interference (RNAi). The company is at the helm of translating RNAi into a new class of innovative medicines, with a core focus on RNAi therapeutics for treating genetically defined diseases. As part of its “Alnylam 5×15” strategy, Alnylam plans to have five RNAi therapeutic products for genetically defined diseases in clinical development by the end of 2015. For more information, visit the company’s Web site at www.alnylam.com.

Rodman & Renshaw is a full-service investment bank dedicated to providing corporate finance, strategic advisory, and related services to public and private companies across multiple sectors and regions. Rodman also provides research, sales, and trading services. According to Sagient Research Systems, Rodman has been ranked the #1 Placement Agent in terms of the aggregate number of PIPE and RD financing transactions completed every year since 2005. For more information on Rodman & Renshaw, visit www.rodmanandrenshaw.com.

Let us hear your thoughts below: